WO2001007028A3 - The use of retinoid receptor antagonists in the treatment of prostate carcinoma - Google Patents

The use of retinoid receptor antagonists in the treatment of prostate carcinoma Download PDF

Info

Publication number
WO2001007028A3
WO2001007028A3 PCT/US2000/019849 US0019849W WO0107028A3 WO 2001007028 A3 WO2001007028 A3 WO 2001007028A3 US 0019849 W US0019849 W US 0019849W WO 0107028 A3 WO0107028 A3 WO 0107028A3
Authority
WO
WIPO (PCT)
Prior art keywords
retinoid receptor
prostate carcinoma
treatment
receptor antagonists
tumor
Prior art date
Application number
PCT/US2000/019849
Other languages
French (fr)
Other versions
WO2001007028A2 (en
Inventor
Roshantha A Chandraratna
Geoffrey Brown
Original Assignee
Allergan Sales Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales Inc filed Critical Allergan Sales Inc
Priority to AU62280/00A priority Critical patent/AU6228000A/en
Publication of WO2001007028A2 publication Critical patent/WO2001007028A2/en
Publication of WO2001007028A3 publication Critical patent/WO2001007028A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to methods for treating prostate cancer comprising administering a therapeutically effective amount of a retinoid receptor antagonist. In addition, the present invention provides methods of inhibiting the growth of a prostate carcinoma cell or tumor, the method comprising contacting the cell or tumor with an effective amount of a retinoid receptor antagonist.
PCT/US2000/019849 1999-07-23 2000-07-21 The use of retinoid receptor antagonists in the treatment of prostate carcinoma WO2001007028A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU62280/00A AU6228000A (en) 1999-07-23 2000-07-21 The use of retinoid receptor antagonists in the treatment of prostate carcinoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14528799P 1999-07-23 1999-07-23
US60/145,287 1999-07-23

Publications (2)

Publication Number Publication Date
WO2001007028A2 WO2001007028A2 (en) 2001-02-01
WO2001007028A3 true WO2001007028A3 (en) 2001-08-30

Family

ID=22512422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/019849 WO2001007028A2 (en) 1999-07-23 2000-07-21 The use of retinoid receptor antagonists in the treatment of prostate carcinoma

Country Status (2)

Country Link
AU (1) AU6228000A (en)
WO (1) WO2001007028A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004293133A1 (en) * 2003-11-25 2005-06-09 High Point Pharmaceuticals, Llc Novel salicylic anilides
BRPI0616454A2 (en) 2005-09-30 2011-06-21 Vitae Pharmaceuticals Inc cancer treatment methods
US20130190395A1 (en) 2011-12-13 2013-07-25 Dartmouth College Autoimmune disorder treatment using rxr agonists
KR102489706B1 (en) 2015-10-31 2023-01-17 아이오 테라퓨틱스, 인크. Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones
ES2898676T3 (en) 2015-11-25 2022-03-08 Io Therapeutics Inc Selective CYP26-resistant rar-alpha agonists in cancer treatment
JP7169647B2 (en) 2016-03-10 2022-11-11 アイオー セラピューティクス インコーポレイテッド Treatment of muscle disorders with a combination of RXR agonists and thyroid hormones
CA3016876C (en) 2016-03-10 2021-12-28 Io Therapeutics, Inc. Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
EP3468600A4 (en) 2016-06-10 2019-11-13 IO Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
JOP20200001A1 (en) 2017-07-11 2022-10-30 Vertex Pharma Carboxamides as modulators of sodium channels
KR20200029544A (en) 2017-07-13 2020-03-18 아이오 테라퓨틱스, 인크. Immunomodulatory retinoid and rexinoid compounds combined with immunomodulators for cancer immunotherapy
AU2018326617B2 (en) 2017-08-31 2022-12-01 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
AU2018335393A1 (en) 2017-09-20 2020-04-02 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
US11896558B2 (en) 2021-12-07 2024-02-13 Io Therapeutics, Inc. Use of an RXR agonist and taxanes in treating Her2+ cancers

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024348A1 (en) * 1995-12-29 1997-07-10 Vision Pharmaceuticals L.P. ((3'-thioxacyclohex-1'-enyl))-but-3'-ene-1'-ynyl)aryl and heteroaryl carboxylic acids and esters having retinoid-like biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5763635A (en) * 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5773594A (en) * 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
WO1999033821A1 (en) * 1997-12-24 1999-07-08 Allergan Sales, Inc. Benzopyran and benzothiopyran derivatives having retinoid antagonist-like activity

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024348A1 (en) * 1995-12-29 1997-07-10 Vision Pharmaceuticals L.P. ((3'-thioxacyclohex-1'-enyl))-but-3'-ene-1'-ynyl)aryl and heteroaryl carboxylic acids and esters having retinoid-like biological activity
US5763635A (en) * 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5773594A (en) * 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
WO1999033821A1 (en) * 1997-12-24 1999-07-08 Allergan Sales, Inc. Benzopyran and benzothiopyran derivatives having retinoid antagonist-like activity

Also Published As

Publication number Publication date
WO2001007028A2 (en) 2001-02-01
AU6228000A (en) 2001-02-13

Similar Documents

Publication Publication Date Title
EP2042194A3 (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
WO2001007028A3 (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
MX9804009A (en) Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor.
ZA200109906B (en) Method for treating chronic pain using MEK inhibitors.
WO2001030381A3 (en) Use of csf-1 inhibitors
WO2001015678A3 (en) Topical use of kappa opioid agonists to treat otic pain
AU2003267203A8 (en) Method for administering thermotherapy to prevent the growth of tumors
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
ZA200109903B (en) Method for treating chronic pain using MEK inhibitors.
MXPA00011248A (en) Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
WO2004068931A3 (en) Amphiregulin antibodies and their use to treat cancer and psoriasis
MXPA01013395A (en) TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES.
EP1539234A4 (en) Methods of preventing or treating cell malignancies by administering cd2 antagonists
AU2003273176A8 (en) Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
MXPA03003632A (en) Method for treatment of tumors using combination therapy.
MXPA04005003A (en) Endothelin antagonists ina method and composition for potentiating an opiate analgesic.
AU2002241736A1 (en) Method for preventing or treating pain by administering an endothelin antagonist
EP1175616A4 (en) Methods for the diagnosis and treatment of metastatic prostate tumors
WO2005011590A3 (en) Compositions and methods for restoring sensitivity to treatment with her2 antagonists
WO2002092016A3 (en) Therapeutic use of rank antagonists
WO2002098362A3 (en) Use of rank antagonists to treat cancer
HK1029944A1 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
WO2001080813A3 (en) Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
WO2001074296A3 (en) Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP